C3 Glomerulonephritis and Evolving Podocytopathy in Lupus: Why Repeat Kidney Biopsy Matters (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0767; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "She was initially treated with mycophenolic acid and prednisone, achieving ~50% reduction in proteinuria, but later developed an increase in proteinuria and AKI (Cr 0.9 → 1.99 mg/dL)...Iptacopan was just FDA approved for C3GN and was started in May 2025...She was transitioned to pegcetacoplan in December 2025...To our knowledge, there is nothing in the literature reporting an association between C3GN and lupus podocytopathy. Treatment directed at the podocytopathy with steroids and calcineurin inhibitors led to clinical improvement."
Biopsy • Cardiovascular • Complement-mediated Rare Disorders • Glomerulonephritis • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus
|
|
Kanika Aggarwal; Vraj Patel; Drew N. Graydon; Jared Hassler; Sheetal Koul; Iris J. Lee
|